Description: Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. It offers plasma products, such as intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.
Home Page: www.grifols.com
Avinguda de la Generalitat, 152
Barcelona,
08174
Spain
Phone:
34 935 712 200
Officers
| Name | Title |
|---|---|
| Mr. Jose Ignacio Abia Buenache | CEO & Director |
| Mr. Alfredo Arroyo Guerra CPA | CFO & VP |
| Mr. Lluis Pons Gomez | Senior Vice President of Strategy & COO Office |
| Ms. Nuria Pascual Lapeña | VP of Corporate Treasury, Risk Management Investor Relation & Sustainability Officer |
| Mr. David Ian Bell | Chief Corporate Development, Legal & Data Protection Officer |
| Ms. Maria Teresa-Rioné Llano | Chief Communications Officer |
| Mr. Camille Alpi | Chief Human Resources & Talent Officer |
| Mr. Vicente Blanquer Torre | Chief Quality Officer |
| Mr. Sergio Roura Adell | President of Commercial Tech Support |
| Mr. Víctor Grifols Deu | Executive Director |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 9.1912 |
|---|---|
| Trailing PE: | 33.12 |
| Price-to-Book MRQ: | 1.0044 |
| Price-to-Sales TTM: | 0.8241 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 23000 |